MORGAN STANLEY PLC/CALL/REVVITY/100/0.1/21.03.25

MORGAN STANLEY PLC/CALL/REVVITY/100/0.1/21.03.25 Stock

DE000MG3SA28

Market Closed - Börse Stuttgart 14:18:10 2024-06-21 EDT
1.8 ^EUR	+3.45%

Current month	+2.96%
1 month	-7.94%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart REVVITY, INC.

Chart MORGAN STANLEY PLC/CALL/REVVITY/100/0.1/21.03.25

Latest news about REVVITY, INC.

Bionano Genomics Says Revvity to Commercialize VIA Software	06-20	MT
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research	06-20	AQ
Bionano Genomics, Inc. Announces Software Marketing Agreement with Revvity, Inc. for Newborn Sequencing Research	06-20	CI
GenKOre Announces Strategic Collaboration with Revvity to Develop Innovative Gene Therapy Treatments	06-18	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-21	1.8	+3.45%
24-06-20	1.74	+2.96%
24-06-19	1.69	-2.31%
24-06-18	1.73	+3.59%
24-06-17	1.67	-9.24%

Delayed Quote Börse Stuttgart

Last update June 21, 2024 at 02:18 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	REVVITY, INC.
Issuer	Morgan Stanley
WKN	MG3SA2
ISIN	DE000MG3SA28
Date issued	2024-05-07
Strike	100 $
Maturity	2025-03-21 (273 Days)
Parity	10 : 1
Emission price	1.47 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	2 €
Lowest since issue	1.38 €
Delta	0.7x
Omega	3.800
Premium	10.9x
Gearing	5.44x
Moneyness	1.081
Difference Strike	-7.98 $
Difference Strike %	-7.98%
Spread	0.16 €
Spread %	8.25%
Theoretical value	1.860
Implied Volatility	37.29 %
Total Loss Probability	41.95 %
Intrinsic value	0.7584
Present value	1.102
Break even	119.89 €
Theta	-0.02x
Vega	0.03x
Rho	0.04x

Company Profile

Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows: - medical diagnosis equipment (61%); - analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc. Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).

Sector

More about the company

Ratings for Revvity, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Revvity, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

107.5 USD

Average target price

124.1 USD

Spread / Average Target

+15.44%

Consensus